Analysis of Cardiac Adverse Reaction Induced by Immune Checkpoint Inhibitors

OBJECTIVE To study the features of adverse drug reaction in cardiovascular system induced by immune checkpoint inhibitors through literature analysis and provide reference for clinical rational use of immune checkpoint inhibitors. METHODS Literature about marketed immune checkpoint inhibitors-induced cardiac ADRs were collected from Pubmed database before September 2017 with "Ipilimumab", "Nivolumab", "Pembrolizumab", "Atezolizumab", "Avelumab" and "Durvalumab" as key words, and analyzed statistically in respect of patients' gender, age, primary disease, drug use and clinical manifestations of cardiac ADRs. RESULTS A total of 17 cases of immune checkpoint inhibitors-induced cardiac ADRs were collected. Ipilimumab was most frequently reported. Nivolumab and Pembrolizumab were the second. Myocarditis was the most common diagnosis of cardiac toxicity(58.8%), followed by arrhythmia and heart failure. The fastest ADRs occurred at 1 week after the first dose, the slowest occurred at 31 weeks, the median was 9 weeks. Of the 17 patients, 9 died. CONCLUSION It should be payed more attention to the ADR of immune checkpoint inhibitors in cardiovascular system.